

PROVINCIAL FUNDING SUMMARY

Nivolumab (Opdivo) for Squamous Cell Carcinoma of the Head and Neck (SCCHN)

pERC Recommendation: Recommends with conditions
For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: September 18, 2017

This information is current as of June 4, 2018.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Mar 1, 2018	<p>Histologically confirmed recurrent or metastatic SCCHN (oral cavity, oropharynx, pharynx, larynx, primary unknown), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)</p> <ul style="list-style-type: none"> • Patients have received at least 1 prior line of platinum chemotherapy in the neoadjuvant, adjuvant, concurrent, or metastatic setting • ECOG 0-2 • Adequate hepatic and renal function • Patients may be PDL1 positive or negative • Patients may be p16 positive or negative • Access to a treatment centre with expertise to manage immune-mediated adverse reactions of nivolumab • A BC Cancer "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment
AB	Funded	May 8, 2018	<p>For the treatment of patients with squamous cell cancer of the head and neck (SCCHN) who either have a recurrence within 6 months of potentially curative neoadjuvant/adjuvant platinum-based therapy or recurrence after receiving platinum-based therapy in a non-curative setting, and who have a good performance status. Nivolumab may also be considered for patients who are ineligible for a platinum-based chemotherapy. Treatment should continue until unacceptable toxicity or confirmed disease progression. Dosing is 3 mg/kg to a cap of 240 mg. every 2 weeks.</p>

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
SK	Funded	Dec 7, 2017	Treatment of patients with squamous cell cancer of the head and neck (SCCHN) who either have a recurrence within six months of potentially curative neoadjuvant/adjuvant platinum-based therapy, or recurrence after receiving platinum-based therapy in a non-curative setting, and who have a good performance status. Treatment should continue until unacceptable toxicity or disease progression.
MB	Funded	Dec 5, 2017	For the treatment of patients with squamous cell cancer of Head and Neck who either have a recurrence within six months of potentially curable neoadjuvant/adjuvant platinum-based therapy or recurrence after receiving platinum-based therapy in a non-curative setting AND who have good performance status.
ON	Funded	Jan 17, 2018	For the treatment of patients with squamous cell cancer of the head and neck (SCCHN) who either have a recurrence within 6 months of potentially curative neoadjuvant/adjuvant platinum-based therapy; or a recurrence after receiving platinum-based therapy in a non-curative setting; and who have good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity.
NS	Funded	Apr 18, 2018	As a single agent treatment option for patients with squamous cell cancer of the head and neck (SCCHN) who either have a recurrence within six months of potentially curative platinum-based therapy, or recurrence after receiving platinum-based therapy in a non-curative setting. Patients should have a good performance status. Treatment duration should continue until unacceptable toxicity or disease progression.
NB	Funded	Dec 18, 2017	For the treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) who experience disease recurrence within six months of potentially curative neoadjuvant / adjuvant platinum-based therapy or, after receiving platinum-based therapy in a non-curative setting. Patients must have a good performance status. Treatment should be discontinued upon disease progression or unacceptable toxicity.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NL	Funded	May 30, 2018	Treatment of patients with squamous cell cancer of the head and neck who either have a recurrence within six months of potentially curative neoadjuvant/adjuvant platinum-based therapy or recurrence after receiving platinum-based therapy in a non-curative setting, and who have a good performance status. Treatment should continue until unacceptable toxicity or disease progression. Dosed at 3 mg/kg every 3 weeks.
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.